There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spero Therapeutics (SPRO – Research Report) and CareDx (CDNA – Research Report) with bullish sentiments. Spero Therapeutics (SPRO) H.C. Wainwright analyst Ram
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report), with a price target of $27. The company’s shares closed on Friday at $9.23. Arce commented: “916-3963, POS
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report), with a price target of $27. The company’s shares opened today at $11.38. Chen commented: “. Post a
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report). The company’s shares closed on Friday at $13.18. According to TipRanks.com, Olson is ranked 0 out of 5 stars
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spero Therapeutics Inc (SPRO – Research Report) and Strongbridge Biopharma Plc (SBBP – Research Report) with bullish sentiments. Spero Therapeutics Inc (SPRO)
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report), with a price target of $30. The company’s shares closed yesterday at $10.91. Olson commented: “We met with SPRO